secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001104659-23-029558
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel reports Q4 2022 net income $1.4M on record TAVALISSE sales of $21.9M; full year revenue $120.2M
--------------------------------------------------------------------------------

- Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.
- Full year 2022 net loss $58.6M ($0.34/share) on revenue $120.2M, compared to net loss $17.9M in 2021.
- TAVALISSE 2022 net product sales $75.8M, up 20% YoY; Q4 bottles shipped to patients/clinics a record.
- REZLIDHIA launched in Dec '22, $0.9M in Q4 sales; added to NCCN Guidelines for AML in Jan '23.
- Cash and investments $58.2M at Dec 31, 2022, down from $125.0M at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/0001104659-23-029558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/tm238702d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer